Current Diabetes Reports

, Volume 6, Issue 6, pp 409–410

An appraisal of aspirin therapy in diabetes

Invited Commentary


  1. 1.
    Colwell JA: Aspirin therapy in diabetes. Diabetes 1997, 20:1767–1771.Google Scholar
  2. 2.
    American Diabetes Association: Standards of care. Diabetes Care 2006, 29(suppl 1):519–520.Google Scholar
  3. 3.
    Pearson TA, Blair SN, Daniels SR, et al.: AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002, 106:388–391.PubMedCrossRefGoogle Scholar
  4. 4.
    US Preventive Services Task Force: Aspirin for the primary prevention of cardiovascular events: summary of the evidence. Ann Intern Med 2002, 136:161–172.Google Scholar
  5. 5.
    Anderson KM, Wilson PW, Odell PM, Kannel WB: An updated coronary risk profile. A statement for health professionals. Circulation 1991, 83:356–362.PubMedGoogle Scholar
  6. 6.
    Stevens RJ, Kothari V, Adler A, et al.: The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci 2001, 101:671–679.PubMedCrossRefGoogle Scholar
  7. 7.
    Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001, 285:2486–2497.CrossRefGoogle Scholar
  8. 8.
    Rolka DB, Fagot-Campagna A, Narayan KM: Aspirin use among adults with diabetes: estimates from the Third National Health and Nutrition Examination Survey. Diabetes Care 2001, 24:197–201.PubMedCrossRefGoogle Scholar
  9. 9.
    Guzder RN, Gatling W, Mullee MA, et al.: Progressive value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed type 2 diabetes: results from a United Kingdom study. Diabet Med 2005, 22:554–562.PubMedCrossRefGoogle Scholar
  10. 10.
    Howard B, Best LG, Gallaway JM, et al.: Coronary heart disease risk equivalence in diabetes depends on consistent risk factors. Diabetes Care 2006, 29:391–397.PubMedCrossRefGoogle Scholar
  11. 11.
    Ridker PM, Cook NR, Lee IM, et al.: A randomized trail of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005, 352:1293–1304.PubMedCrossRefGoogle Scholar
  12. 12.
    Hennekens CH, Knatterud GL, Pfeffer MA: Use of aspirin to reduce risks of cardiovascular disease in patients with diabetes. Diabetes Care 2004, 27:2752–2754.PubMedCrossRefGoogle Scholar
  13. 13.
    Mason PJ, Freedman JE, Jacobs AK: Aspirin resistance: current concepts. Rev Cardiovasc Med 2004, 5:156–163.PubMedCrossRefGoogle Scholar
  14. 14.
    Tantry US, Bliden KP, Gurbel PA: Overestimation of platelet aspirin resistance by thromboelastograph mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 2005, 46:1705–1709.PubMedCrossRefGoogle Scholar
  15. 15.
    DiMinno G, Silver MJ, Cerbone AM, et al.: Trial of repeated low-dose aspirin in diabetic angiopathy. Blood 1986, 68:886–891.PubMedGoogle Scholar

Copyright information

© Current Science Inc 2006

Authors and Affiliations

  1. 1.Medical University of South CarolinaCharlestonUSA

Personalised recommendations